| Autor: |
Ensminger, S., Fujita, B., Aboud, A., Paitazoglou, C., Eitel, I., Jurczyk, D., Mezger, M., Yebran, F., Kutschka, I., Tiburcy, M., Legler, T., Riggert, J., Placzek, M., Friede, T., Jebran, A.F., Seidler, T., Zimmermann, W.H. |
| Předmět: |
|
| Zdroj: |
Thoracic & Cardiovascular Surgeon; 2024 Supplement1, Vol. 72, pS1-S68, 68p |
| Abstrakt: |
The article discusses the BioVAT-HF trial, which aims to investigate the use of induced pluripotent stem cell-derived Engineered Human Myocardium (EHM) as "Biological Ventricular Assist Tissue" (BioVAT) in patients with advanced heart failure. The trial involves the implantation of EHM in patients with terminal heart failure and evaluates its safety and efficacy. The study reports the experience of enrolling patients at the University Heart Center Luebeck (UKSH) and highlights that the implantation of EHM was feasible and apparently safe. However, one patient died of progressive cardio-renal failure after the procedure. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
